Download Files:
Products Details
Product Description
– Terazosin-d8 is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].
Web ID
– HY-B0371S
Shipping
– Room temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C19H17D8N5O4
References
– [1]Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851.|[2]Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.|[3]Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
CAS Number
– 1006718-20-2
Molecular Weight
– 395.48
SMILES
– NC1=NC(N2C([2H])([2H])C([2H])([2H])N(C([2H])([2H])C2([2H])[2H])C(C3CCCO3)=O)=NC4=C1C=C(OC)C(OC)=C4
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease; Endocrinology
Solubility
– 10 mM in DMSO
Target
– Adrenergic Receptor;Isotope-Labeled Compounds
Pathway
– GPCR/G Protein;Neuronal Signaling;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
